With 6 million shares offered at $64.50 each, OSI Pharmaceuticals Inc. is raising $387 million while waiting with partner Genentech Inc. for word from the FDA regarding Tarceva, their drug for non-small-cell lung cancer. (BioWorld Today)

Dyax Corp.'s human antibody libraries drew a deal of undisclosed financial size with Biogen Idec Inc., which is providing research funding to Dyax for at least three years in an arrangement that's slightly different from earlier library deals. (BioWorld Today)

Amgen Inc. opted for a license arrangement rather than an equal partnership with Nuvelo Inc. for the Phase III-ready clot-dissolver alfimeprase, the lead product candidate that is the subject of a deal started almost three years ago. (BioWorld Today)